biostudies-literatureGeorge JMNational Institute of Allergy and Infectious DiseasesNational Institute of Diabetes and Digestive and Kidney DiseasesNIAID NIH HHSNational Heart, Lung, and Blood InstituteFogarty International CenterNational Cancer InstituteNCI NIH HHSNational Institute of Mental HealthNational Institutes of HealthNational Institute on Drug AbuseNational Institute of General Medical SciencesNational Institute on Aginge604-e613https://www.ebi.ac.uk/biostudies/studies/S-EPMC7744993biostudies-literatureUnknown71(10)<h4>Background</h4>Direct oral anticoagulants (DOACs) have become first-line treatment for venous thrombotic events. DOAC prescribing trends among people living with human immunodeficiency virus (PWH) are not well described. The coadministration of DOACs with the antiretroviral (ARV) pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be complicated by pharmacokinetic interactions.<h4>Methods</h4>A longitudinal cohort study was conducted using the D.C. Cohort Database in Washington, D.C., from January 2011 to March 2017, to describe oral anticoagulant prescribing among PWH ≥ 18 years old and the prevalence of DOAC use with RTV or COBI. Data collection included demographic and clinical characteristics, ARV and anticoagulant prescriptions, and International Classification of DiClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaUtilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort.PMC7744993HHSN261200800001EUM1 AI069503P30 AI117970R24 AI1525985UM1AI069503U01 AI069503AI117970Monroe AGeorge JRuiz MERana SGeorge JMBinkley JDistrict of Columbia (D.C.) Cohort Executive CommitteeRahkmanina NMa YTaylor RKumar PPurinton SHapp LPNaughton JWilbourn BGoldstein DMasur HPau AKKharfen MGreenberg AKuriakose SSParenti DFernandez RCastel AHadigan CHebou ADieffenbach CBenator DWilcox RKuriakose STeferi GAkridge CCastel ADParfitt DByrne MD'Angelo LPau APeterson JHou QBordon JHorberg MHorberg MASerlin MRayeed NJaurretche MLevy MfalseUtilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort.<h4>Background</h4>Direct oral anticoagulants (DOACs) have become first-line treatment for venous thrombotic events. DOAC prescribing trends among people living with human immunodeficiency virus (PWH) are not well described. The coadministration of DOACs with the antiretroviral (ARV) pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be complicated by pharmacokinetic interactions.<h4>Methods</h4>A longitudinal cohort study was conducted using the D.C. Cohort Database in Washington, D.C., from January 2011 to March 2017, to describe oral anticoagulant prescribing among PWH ≥ 18 years old and the prevalence of DOAC use with RTV or COBI. Data collection included demographic and clinical characteristics, ARV and anticoagulant prescriptions, and International Classification of Di2020-01-01T00:00:00Z2020 Dec2026-07-16T03:40:52.131Z2025-04-04T14:15:22.946ZS-EPMC77449933217990110.1093/cid/ciaa284